Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371381 | 0.94 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DROCK2 | |
| SCHEMBL296021 | 0.94 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DROCK2 | |
| SCHEMBL12621404 | 0.93 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DROCK2 | |
| SCHEMBL12654371 | 0.92 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL12513023 | 0.91 | PDE4A (0.88) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL296482 | 0.89 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL12513216 | 0.88 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL370240 | 0.88 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL371380 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL2312794 | 0.87 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992622-B1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2011-07-27 | — | — | EP | claimed |
| US-7939540-B2 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | claimed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | claimed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | claimed |
| US-10357495-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | Dermavant Sciences GmbH (CH) | 2019-07-23 | — | — | US | disclosed |
| US-20190134036-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-3463366-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10206925-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | EISAI R&D MANAGEMENT CO, LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| WO-2017214289-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348311-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2017-12-07 | — | — | US | disclosed |
| US-8513269-B2 | Preparation for external use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2202229-B1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MAN CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-7939540-B2 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7939540-B2 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2202229-A1 | NOVEL PREPARATION FOR EXTERNAL USE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | disclosed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206925-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | ITCH, HRH4, HRH1 | PDE4A 1280/4885PDE4B 1378/4885PDE4C 2057/4885 |
| US-20170348311-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-10357495-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20190134036-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | SLC26A4, SLC6A15, SLC6A19 | PDE4A 3486/4885PDE4B 3375/4885PDE4C 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.